Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From Hodgkin Lymphoma/sALCL to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin (Adcetris) is an anti-CD30 antibody-drug conjugate internationally approved for relapsed/refractory classical Hodgkin lymphoma and systemic anaplastic large cell lymphoma, though it is currently not registered in Singapore. The TxGNN model predicts it may be effective for Follicular Lymphoma (FL), based on the CD30-targeting mechanism applicable to CD30-positive FL subtypes such as Grade 3B and histologically transformed FL. Currently, 6 clinical trials and 20 publications are associated with this direction, though meaningful direct evidence is confined to 1 active Phase 2 trial and 2 terminated trials with enrolled patients.

Quick Overview

Item	Content
Original Indication	Hodgkin lymphoma and systemic anaplastic large cell lymphoma (international approval; not registered in Singapore)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L3
Singapore Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack. Based on known information, brentuximab vedotin is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody linked to monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxic agent. Upon binding to CD30 on the tumour cell surface, the conjugate is internalised and MMAE is released intracellularly, triggering cell cycle arrest and apoptosis. Efficacy is therefore entirely dependent on tumour CD30 expression, making biomarker-driven patient selection the central requirement for any new indication.

Follicular lymphoma in its classic low-grade form is typically CD30-negative. However, Grade 3B FL and histologically transformed FL (particularly transformation to diffuse large B-cell lymphoma or anaplastic large cell lymphoma) can acquire meaningful CD30 positivity, creating a biologically rational and druggable subpopulation. The mechanistic hypothesis has been adopted in clinical practice: NCT04587687 is an ongoing Phase 2 trial specifically investigating brentuximab vedotin plus bendamustine in relapsed/refractory FL, and NCT01805037 explicitly enrolled CD30-positive FL and mantle cell lymphoma patients alongside other CD30+ lymphoma types.

A published case report (PMID 32476657) provides direct supporting evidence: a patient with Grade I FL that transformed to CD30+ ALK1-negative anaplastic large cell lymphoma achieved complete response to brentuximab vedotin combined with high-dose methotrexate. While this represents a transformed rather than de novo FL setting, it validates the CD30-targeting rationale in patients with FL-origin tumours that acquire CD30 expression.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04587687	Phase 2	Recruiting	23	BV + bendamustine for relapsed/refractory follicular lymphoma; the only trial directly focused on this combination in FL; results pending (expected completion December 2026)
NCT01805037	Phase 1/2	Terminated	20	BV + rituximab as frontline therapy for CD30+ and/or EBV+ lymphomas; design explicitly included CD30+ FL patients, confirming the mechanistic hypothesis has been clinically operationalised; partial safety data available
NCT02594163	Phase 2	Terminated	25	Randomised BV + rituximab + bendamustine vs. rituximab + bendamustine for R/R CD30+ diffuse large B-cell lymphoma; terminated early with 25 enrolled; preliminary safety reference for BV-based B-cell lymphoma combinations

Three additional trials (NCT02623920, NCT04138875, NCT04795869) were withdrawn before any patient enrolment and contribute no interpretable data.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
32476657	2020	Case Report	Gulf Journal of Oncology	Complete response in Grade I FL that transformed to CD30+ ALK1– ALCL following treatment with BV + high-dose methotrexate; directly supports the CD30-targeting rationale in the FL context
35663281	2022	Review	Leukemia Research Reports	Comprehensive review of immunotherapy in indolent non-Hodgkin lymphoma including FL; discusses CD30-directed strategies and the emerging role of novel agents in this disease category
38028985	2023	Case Report	Case Reports in Hematology	FL transformation to EBV+ DLBCL and EBV+ classical Hodgkin lymphoma; illustrates the biological plasticity of FL and its capacity to acquire CD30 expression upon transformation
28967896	2018	Review	Bone Marrow Transplantation	Review of post-autologous SCT maintenance in lymphomas including FL; contextualises the role of novel agents, including BV, in the post-transplant consolidation strategy

The majority of retrieved publications (16 of 20) concern peripheral T-cell lymphoma, where BV has established evidence. These were excluded from the table as they do not directly inform the FL indication.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted cytotoxic — Antibody-Drug Conjugate (ADC); anti-CD30 antibody linked to MMAE (monomethyl auristatin E), a tubulin polymerisation inhibitor
Myelosuppression Risk	Moderate to High — neutropenia is the most frequently reported dose-limiting toxicity; anaemia and thrombocytopenia also observed
Emetogenicity Classification	Low to Moderate
Monitoring Items	Complete blood count with differential (prior to each cycle), peripheral neuropathy assessment, liver function tests (ALT/AST/bilirubin), renal function, and serum electrolytes
Handling Protection	Must be handled in accordance with cytotoxic drug handling regulations; reconstitution should be performed in a biological safety cabinet; appropriate personal protective equipment required

Safety Considerations

Please refer to the package insert for safety information. No Singapore-specific package insert data is available as the drug is not currently registered in Singapore. The internationally approved prescribing information (FDA/EMA label for Adcetris) should be consulted, with particular attention to peripheral neuropathy (a cumulative dose-dependent toxicity), pulmonary toxicity, and infusion-related reactions.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: An ongoing Phase 2 trial (NCT04587687) directly investigates brentuximab vedotin in relapsed/refractory follicular lymphoma, and the CD30-targeting mechanism is biologically plausible in CD30-positive FL subtypes. However, the majority of FL tumours are CD30-negative, and broader application without mandatory biomarker screening carries a high risk of exposing non-responding patients to unnecessary toxicity.

To proceed, the following is needed:

Mandatory CD30 IHC testing prior to any treatment consideration — brentuximab vedotin should only be considered in FL patients with confirmed CD30 expression
Full MOA and safety documentation — obtain package insert from FDA/EMA approval for complete warnings, contraindications, and drug interaction profile (currently data gaps DG001 and DG002)
Await NCT04587687 results — this trial (expected completion December 2026) will provide the first FL-specific efficacy and safety data for this combination; no clinical decision should be made without this information
Singapore regulatory pathway — the drug is not registered in Singapore; any use would require a Clinical Trial Certificate, compassionate use application, or Special Access Route via HSA
Patient stratification strategy — define the target FL subgroup (Grade 3B, transformed FL, or CD30 ≥ threshold by IHC) before designing any local feasibility assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.